JAZZ Jazz Pharmaceuticals plc

NASDAQ
$244.96

Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is $5.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.1% since its last earnings release on August 3, 2026.

Jazz Pharmaceuticals plc Beat Expectations, Raises Guidance
Monday, August 3, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:05 PM ET
Earnings Whisper
-
vs $5.68 (GAAP)
Rev est $1.2B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $254.92

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases -- often with limited or no options.

Sector

Healthcare

Industry

Biotechnology